Mexico is one of the largest consumers of generic medicines in the world and is home to the second largest pharmaceuticals market in Latin America, after Brazil. Pharmaceuticals accounted for 14.9% of healthcare spending in 2017, equivalent to sales of MXN189.68bn (USD10.03bn). In 2017, the country's per capita spending amounted to USD78, while pharmaceutical sales as a percentage of GDP came to 0.87%. The government's efforts to improve competitiveness in Mexico's pharmaceutical sector combined with the country's economic outperformance compared with large countries like Brazil will improve Mexico's attractiveness to drugmakers. Regulatory changes in particular have been aimed at laying incentives for multinational drugmakers to prioritise the country's pharmaceutical market. The weakness of the peso over recent years has had a significant negative impact on multinational pharmaceutical revenues through the translation into reporting currencies. The Mexican pharmaceutical market contracted in US dollar terms for three consecutive years from 2014-2016 and only posted weak growth in 2017. Despite this, we forecast that the peso weakness is coming to an end and the longer-term outlook for multinationals operating in the country is more positive.

Key View

SWOT

Industry Forecast

Pharmaceutical Market Forecast

Healthcare Market Forecast

Prescription Drug Market Forecast

Patented Drug Market Forecast

Generic Drug Market Forecast

OTC Medicine Market Forecast 

Pharmaceutical Trade Forecast 

Industry Risk/Reward Index

Pharmaceuticals & Healthcare Risk/Reward Index 

Mexico Innovative Pharmaceuticals Risk/Reward Index

Regulatory Development

Regulatory Review

Market Overview

Competitive Landscape

Company Profile

Boehringer Ingelheim

Genomma Labs

Mexico Demographic Outlook

Pharmaceuticals & Healthcare Glossary 

Pharmaceuticals & Healthcare Methodology